Gennex Laboratories Ltd
NSE: BSE: 531739
₹9.40
(0.86%)
Mon, 23 Mar 2026, 09:36 pm
Market Cap2.14B
PE Ratio12.68
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KGennex Laboratories Analysis
dividend
- Unable to evaluate Gennex Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Gennex Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Gennex Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Gennex Laboratories is profitable, therefore cash runway is not a concern.
- Gennex Laboratories is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (41.8%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 7.2x debt.
- Gennex Laboratories's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (14.9% vs 12.7% today).
- Interest payments on debt are well covered by earnings (EBIT is 5.3x coverage).
- Gennex Laboratories's level of debt (12.7%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Gennex Laboratories board of directors is about average.
- Arihant's remuneration is about average for companies of similar size in India.
- Arihant's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Gennex Laboratories management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Gennex Laboratories is not covered by any analysts.
- Gennex Laboratories has significant price volatility in the past 3 months.
past
- Gennex Laboratories's 1-year earnings growth exceeds its 5-year average (26.2% vs 8.5%)
- Gennex Laboratories's year on year earnings growth rate has been positive over the past 5 years.
- Gennex Laboratories's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (26.2% vs 22.7%).
- Gennex Laboratories used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Gennex Laboratories's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Gennex Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- 531739 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 531739 outperformed the Market in India which returned -14.5% over the past year.
- BSE:531739 is up 86.9% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:531739 is up 86.9% outperforming the market in India which returned 8% over the past month.
- Gennex Laboratories's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Gennex Laboratories's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Gennex Laboratories is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Gennex Laboratories is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Gennex Laboratories is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800